Results 241 to 250 of about 5,867,590 (302)
Drug supply changes associated with a key policy on drug shortages in China: evidence from an interrupted time-series study. [PDF]
Front PharmacolHu S +8 more
europepmc +1 more source
Brand-Generic Patent Settlements Reported to the US Federal Trade Commission.
JAMA Health ForumDaval CJR, Egilman AC, Kesselheim AS.
europepmc +1 more source
Reimbursement status, access delays and prices of orphan drugs in France: a population-stratified analysis of indications approved between 2021 and 2024. [PDF]
Orphanet J Rare DisSultan I, Paubel P, Degrassat-Théas A.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Drug Discovery, 2018
This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments.
Kerri, Brown, Graeme, Green
openaire +2 more sources
This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments.
Kerri, Brown, Graeme, Green
openaire +2 more sources
Nature Reviews Drug Discovery, 2017
Two PD-1 directed checkpoint inhibitors have recently been approved for squamous cell carcinoma of the head and neck (SCCHN). Further checkpoint inhibitors, as well as other molecularly targeted agents and cytokine-based immunotherapies, are currently in the late-stage pipeline and are poised to change the treatment paradigm for SCCHN.
Jennifer, Bamford, Rachel M, Webster
openaire +2 more sources
Two PD-1 directed checkpoint inhibitors have recently been approved for squamous cell carcinoma of the head and neck (SCCHN). Further checkpoint inhibitors, as well as other molecularly targeted agents and cytokine-based immunotherapies, are currently in the late-stage pipeline and are poised to change the treatment paradigm for SCCHN.
Jennifer, Bamford, Rachel M, Webster
openaire +2 more sources
Nature Reviews Drug Discovery, 2015
This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially.
Salman, Rizvi +2 more
exaly +3 more sources
This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially.
Salman, Rizvi +2 more
exaly +3 more sources
Peptides as Drugs: Is There a Market?
Journal of Peptide Science, 2001What is the value of the ethical pharmaceutical market? What is the share of the peptides and proteins market within it? Is it worthwhile to invest in research in that field with the hope of finding new drugs? Do we, as scientists, have a future when starting our career in the isolation, synthesis or production of peptides and proteins?
openaire +2 more sources
The Lancet, 2000
A new therapy is enormously expensive: it costs up to $350 million to bring a new drug to market, or more than $500 million if failures are taken into account, most of the money going to meet the regulatory requirements for phase II and phase III clinical trials.
E A, Gale, A, Clark
openaire +2 more sources
A new therapy is enormously expensive: it costs up to $350 million to bring a new drug to market, or more than $500 million if failures are taken into account, most of the money going to meet the regulatory requirements for phase II and phase III clinical trials.
E A, Gale, A, Clark
openaire +2 more sources